Volume dodolan perusahaan inmunebio.com (INMB)

INmune Bio, Inc. (INMB) operates under negative cash flow, relying on external capital for development. Meanwhile, the company strictly adheres to bioethical standards and clinical trial transparency. The company's sales volume on this chart demonstrates revenue dynamics, where 0.00 expresses the latest metric level. The business strategy relies on TNF neutralization to combat Alzheimer's disease and oncology.

This indicator is based on the daily aggregation of operating receipts, eliminating the time lag associated with quarterly reporting. The metric measures the actual liquidity of the business, allowing investors to promptly identify a loss of cash flow stability. For INmune Bio, Inc. (INMB), this is critical during the development of innovative immune drugs against Alzheimer's and cancer. Analyzing the company's current sales helps avoid entering the asset at a valuation peak during a sharp reduction in funding.